viewActinium Pharmaceuticals Inc

Actinium Pharmaceuticals shares climb after positive FDA discussions on Actimab-MDS pivotal trial

The New York biotech’s Actimab-A development strategy in combinations with Venetoclax for treating acute myeloid leukemia has shown ‘potential synergy’

A reseracher in a lab
The application of Actimab-A to leukemia patients in remission suggests the antibody can be used across the spectrum of acute myeloid leukemia

Actinium Pharmaceuticals Inc (NASDAQ:ATNM) stock shot up Wednesday after it said positive FDA discussions for its cancer drug Actimab, for Myelodysplastic Syndrome (MDS), a bone marrow failure disorder, enabled accelerated pivotal trials and broadened the target patient population.

Actinium highlighted the outcome of its discussions with the FDA for the Actimab-MDS program, which resulted in guidance for an accelerated pathway to a pivotal trial after a short dose-finding Phase 1 portion.

The initial proposal to the FDA was to conduct a larger Phase 2 trial prior to a pivotal trial in patients with a TP53 mutation, however, the company was encouraged by the FDA to expand the trial to include all high-risk patients with poor or very poor and complex cytogenetics.

The company said the program will use the ARC Ac-225-lintuzumab for targeted conditioning in combination with a reduced intensity dose of fludarabine and melphalan prior to a bone marrow transplant in patients with high-risk Myelodysplastic Syndrome. 

"In our studies to date, we've seen that Ac-225–lintuzumab can achieve remissions with minimal extramedullary toxicities even in patients progressing to acute myeloid leukemia from MDS. Typically, high-risk MDS patients undergoing a bone marrow transplant do poorly with standard conditioning resulting in poor outcomes,” said Actinium's Chief Medical Officer Dr Mark Berger.

As many as 21,000 patients are diagnosed with acute myeloid leukemia yearly in the US and over 350,000 cases of acute myeloid leukemia exist worldwide.

Berger said the goal of the Actimab-MDS program is to "use our ARC AC-225–Lintuzumab to target progenitor cells" with the goal of achieving improved conditioning and bone marrow transplant outcomes, as successful bone marrow transplant is the only potentially curative treatment option for these patients. He said the biotech was building on the data it already had from its CD33 program and was excited to have a quicker pathway to a pivotal trial that targets a larger patient population than originally envisaged.

Actinium's two combination trials with Venetoclax, a BCL-2 inhibitor that was jointly developed by AbbVie and Genentech, will leverage Actimab-A's unique mechanism of action to explore synergies between the two agents for patients with relapsed acute myeloid leukemia.

Actinium shares shot up 4.8% to $0.64.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 


Quick facts: Actinium Pharmaceuticals Inc

Price: 0.26 USD

Market: NYSE
Market Cap: $42.82 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Castillo Copper's Ged Hall updates on key assets and progress on London dual...

Ged Hall works with London stockbroker SI Capital and is also a non-exec director at Castillo Copper Ltd's (ASX:CCZ). He discusses how the two came to work together as well as updates on what Castillo's doing as far as the Mt Oxide project in Queensland, Australia. 

2 days, 1 hour ago

2 min read